Trials / Completed
CompletedNCT02195947
Antagonist Protocol in Poor Responders
Does the Addition of Growth Hormone to the Invitro Fertilization/ Intracytoplasmic Sperm Injection Antagonist Protocol Improve Outcome in Poor Responders? A Randomized Controlled Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 141 (actual)
- Sponsor
- Cairo University · Academic / Other
- Sex
- Female
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The effect of use of the growth hormone with antagonist protocol on the outcome of the IVF/ICSI cycles in poor responders.
Detailed description
Two groups of poor responder female patients planned to receive the antagonist IVF/ICSI protocol are randomized to whether or not to add growth hormone to their protocol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Growth Hormone | Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration. |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2015-07-01
- Completion
- 2015-07-01
- First posted
- 2014-07-21
- Last updated
- 2021-11-11
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT02195947. Inclusion in this directory is not an endorsement.